Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.
Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.
X4 Pharmaceuticals (Nasdaq: XFOR) has completed enrollment in its pivotal Phase 3 trial for mavorixafor, targeting WHIM syndrome, with 31 patients enrolled, surpassing the original goal of 18-28. Top-line data is expected in Q4 2022, followed by a potential U.S. NDA filing in Q1 2023. WHIM syndrome is a rare primary immunodeficiency caused by mutations in the CXCR4 gene. Mavorixafor has received various designations from the FDA, highlighting its therapeutic potential in immunodeficiencies.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on September 30, 2021, the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards comprise options to purchase 95,200 shares and restricted stock units covering 6,000 shares of common stock. The exercise price for options is set at $5.29 per share, matching the closing price on the grant date. Options will vest over four years, while restricted stock units will vest annually over the same period, contingent upon continued employment.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 11:35 a.m. ET. Additionally, the company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 30, 2021, at 10:00 a.m. ET. Live webcasts of both events will be accessible through the investors section of X4 Pharmaceuticals' website and will be archived for 90 days. X4 is focused on developing therapies for diseases linked to the CXCR4 pathway.
X4 Pharmaceuticals (Nasdaq: XFOR) promotes Mary DiBiase, Ph.D., to Chief Operating Officer, enhancing her responsibilities to include program management and IT oversight. DiBiase, with over 25 years in drug development, has been pivotal in advancing the company's lead candidate, mavorixafor, into late-stage clinical trials. CEO Paula Ragan emphasized her contributions to company growth and the potential commercialization of mavorixafor for treating diseases like WHIM syndrome. The company remains focused on developing innovative therapies targeting rare diseases.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on August 31, 2021, that its Board's Compensation Committee issued an inducement award to new employees under its 2019 Inducement Equity Incentive Plan. The award consists of options to purchase a total of 20,350 shares of common stock at an exercise price of $5.13 per share, equal to the closing stock price on that date. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on continued employment.
BOSTON, Sept. 01, 2021 - X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in investor meetings at the Citi 16th Annual BioPharma Conference from September 8-10, 2021 and a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. A live webcast of the fireside chat will be available on the company's investor section of their website for 90 days post-event. X4 specializes in therapies targeting diseases related to the CXCR4 pathway, with its lead candidate mavorixafor under evaluation in multiple clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) will participate in a fireside chat at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 2:00 PM ET. The event will be accessible via a live webcast on the company's investor website, with an archive available for 90 days. X4 Pharmaceuticals focuses on developing therapies targeting the CXCR4 pathway, particularly for rare diseases. Their lead candidate, mavorixafor, is currently in various clinical trials, including a Phase 3 trial for WHIM syndrome.
On August 3, 2021, X4 Pharmaceuticals (XFOR) announced key milestones in its clinical trials for mavorixafor. Enrollment in the pivotal Phase 3 trial for WHIM syndrome surpassed the minimum requirement, with top-line data expected in Q4 2022. The Phase 1b trial for Waldenström’s macroglobulinemia has also met its minimum enrollment, with results anticipated in Q4 2021. Financially, the company reported a net loss of $19.6 million for Q2 2021, up from $15.1 million in Q2 2020, indicating rising research and development costs.
X4 Pharmaceuticals (Nasdaq: XFOR) will report its financial results for Q2 ended June 30, 2021, on August 3, 2021. The company will also provide updates on recent business highlights during a conference call scheduled at 8:30 a.m. ET on the same day. Investors can access the call by dialing (866) 721-7655 or internationally at (409) 216-0009, using conference ID 2236266. X4 is developing mavorixafor, a novel therapy targeting the CXCR4 pathway, currently being evaluated in multiple clinical trials for rare diseases and cancers.
X4 Pharmaceuticals (Nasdaq: XFOR) announced the issuance of inducement awards to new employees under the 2019 Inducement Equity Incentive Plan on June 30, 2021. The awards include options to purchase a total of 10,850 shares at an exercise price of $6.50, equal to the closing price on that date. The options will vest over four years, with 25% vesting after one year. X4 is focused on developing therapies targeting the CXCR4 pathway, including its lead candidate mavorixafor, currently in multiple clinical trials for rare diseases.
